negotiated North American distribution rights to Swedish company Athera
’s CVDefine® research-use ELISA
kit for the quantitative analysis of anti-PC in human blood. The cardiovascular disease biomarker test has been developed to help the early detection of lesions in the artery wall caused by inflammation. A CE-marked CVDefine kit is available in Europe.
CVDefine is the first product in Athera’s diagnostic pipeline.
The company, part of the Karolinska Development portfolio, is focused on developing novel products for the treatment and prevention of cardiovascular disease.